Tdap + meningococcal polysaccharide diphtheria toxoid conjugate

This is a combination of two separate vaccines administered concomitantly: Tetanus and Diphtheria Toxoid Adsorbed (Tdap) vaccine and Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (MenACWY). The meningococcal component contains polysaccharides from meningococcal serogroups A, C, Y, and W-135 that are conjugated to diphtheria toxoid protein. Clinical studies have shown that when these vaccines are administered together, injection site pain is reported more frequently after Td vaccination than after meningococcal vaccination. The overall rate of systemic adverse events is higher when the vaccines are given concomitantly compared to when meningococcal vaccine is administered 28 days after Td vaccine. Common reactions include headache and fatigue. Studies have shown that the proportions of participants with a 4-fold or greater increase in SBA-BR titer to meningococcal Serogroups C, Y and W-135 were higher when Menactra was given concomitantly with Td vaccine compared to when Menactra was given one month following Td vaccine, while anti-tetanus and anti-diphtheria antibody responses were similar in both study groups.

Other names

Tetanus and Diphtheria Toxoid Adsorbed Vaccine + Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine